Bracco Diagnostics, the US subsidiary of Bracco Imaging, and ulrich medical have received US Food and Drug Administration (FDA) clearance of the Bracco Max 3 injector.
Bracco branded Max 3 is a rapid exchange, syringeless injector designed for magnetic resonance imaging (MRI) procedures.
ulrich medical is a German medical device company specialising in contrast media injectors and spinal implants.
In November 2023, Bracco formed a long-term partnership with ulrich medical to introduce a Bracco-branded, advanced MRI injector in the US. This collaboration aims to enhance healthcare providers’ quality and efficiency.
Bracco Imaging vice chairman and CEO Fulvio Renoldi Bracco said: “This clearance underscores Bracco’s commitment to pushing the boundaries of innovation in 2024 and beyond while implementing sustainable production in all aspects of our business model.
“At Bracco, we always strive for advancements, and it’s remarkable to see how innovative diagnostic imaging solutions have transformed the MRI industry.”
The Max 3 is an MRI injector with intuitive, efficient, and easy-to-manage features. It allows direct injection from original contrast media vials, thereby removing the need for syringe refills.
With no power cables, it can be positioned anywhere in the MRI room, operating up to a maximum magnetic field strength of 50mT.
The easy-click-cassette flex includes a dedicated connector to the patient tubing with SafeConnect, ensuring contact protection and preventing retrograde contamination.
This innovative injector can be used within 24 hours or for up to 96 bottles of contrast media, streamlining workflow and allowing technologists to focus more on patients during procedures.
Bracco Diagnostics said that the Max 3 injector is not only user-friendly but also supports sustainability in radiology.
By reducing plastic waste, it helps hospitals minimise disposable costs and contribute to greener practices in MRI suites.
ulrich medical CEO Klaus Kiesel said: “We’re thrilled to bring an intuitive, easy-to-use, and environmentally friendly solution to the radiology community in collaboration with Bracco.”
Italy-based Bracco Imaging, part of the Bracco Group, offers diagnostic imaging solutions. Its portfolio spans key modalities, including X-ray imaging, MRI, contrast enhanced ultrasound (CEUS), and nuclear medicine with radioactive tracers and advanced PET imaging agents.
In October, Bracco Diagnostics and Subtle Medical announced that their artificial intelligence (AI)-powered software, AiMIFY, has received FDA Class II clearance as a medical device for brain MRI.
